NasdaqGS:AMGNBiotechs
Amgen (AMGN) And Kyowa Kirin Reveal Initial Results From Rocatinlimab ASCEND Study
Amgen (AMGN) and Kyowa Kirin Co., Ltd. announced promising preliminary results from their ASCEND study, focusing on a new therapy for atopic dermatitis, which could potentially pique investor interest. Despite this development, Amgen's stock saw a 2.42% decline last week, subtly countering the broader market movements where indices like the S&P 500 and Nasdaq reached all-time highs. The company's recent collaborations and forward-looking statements provide a context of optimism and...